Morgan Stanley upgraded Celsius Holdings to 'Overweight' with a new price target of $70, and raised Microsoft Corporation's target to $625 after its shares surged over 30% following positive quarterly results. In contrast, the firm downgraded Novo Nordisk to 'Underweight', cutting its price target to $47 due to slowing prescription growth and increased competition in the GLP-1 diabetes market. These updates underscore Morgan Stanley's influential role in navigating the financial landscape amidst ongoing market volatility.